Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06904287 · ClinicalTrials.gov registry record · Phase 3
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
A Phase 3 study of Migraine, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06904287 is a Phase 3 study of Migraine that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 100 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06904287, a Phase 3 study of Migraine, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to find out if using magnesium in addition to prochlorperazine will help reduce your migraine pain.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Magnesium
Study Locations (1)
Illinois
- Advocate Christ Medical Center Emergency Department - Oak Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06904287
The ClinicalTrials.gov registry entry for NCT06904287 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (72% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06904287 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06904287 about?
NCT06904287 is a clinical study titled "Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines". The purpose of this research study is to find out if using magnesium in addition to prochlorperazine will help reduce your migraine pain.
What is the current status of trial NCT06904287?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2025-12-16. Estimated completion is 2027-06.
What conditions does trial NCT06904287 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06904287?
The interventions under investigation include: Placebo (DRUG), Magnesium (DRUG).
Who is sponsoring clinical trial NCT06904287?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06904287 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
-
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.